NUVB - Nuvation Bio Inc.
About Nuvation Bio Inc. (https://www.nuvationbio.com)
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| David T. Hung | Founder, President, Chief Executive Officer & Chairman | 1958 | $1,202,100 USD |
| Philippe Sauvage | Chief Financial Officer & Principal Financial Officer | 1978 | $810,018 USD |
| Gary Hattersley | Chief Scientific Officer | 1967 | $805,803 USD |
| David Liu | Chief Medical Officer | 1970 | $677,151 USD |
| Colleen Sjogren | Chief Commercial Officer | 1971 | $615,841 USD |
| David C. Hanley | Chief Technical Operations Officer | 1970 | $586,040 USD |
| Kerry A. Wentworth | Chief Regulatory Officer | 1973 | – |
| Moses Makunje | Vice President of Finance and Principal Accounting & Financial Officer | 1979 | – |
| Robert DeVita | Vice President of Corporate Development & Investor Relations | – | – |
| Stacy Markel | Chief People Officer | 1965 | – |
| Stephen Dang | Chief Legal Officer & Corporate Secretary | – | – |